The study is one of the most comprehensive demonstrations yet of how AI analysis of a selfie could help to assess a patient's health and guide their medical care. The study is one of the most comprehensive demonstrations yet of how AI analysis of a selfie could help to assess a patient's health and guide their medical care. System can estimate a person's biological age and predict chances of cancer survival from a single photograph Doctors have developed an artificial intelligence tool that can predict a cancer patient's chances of survival from a single photograph of their face. The AI system was custom-built by experts at Mass General Brigham, a nonprofit, integrated academic healthcare system in Massachusetts, to estimate biological age and directly predict survival outcomes in patients diagnosed with cancer. It is one of the most comprehensive demonstrations to date of how AI analysis of a selfie could help assess a patient's health and potentially guide their medical care, and was trained on data from more than 40 million facial photographs across a range of ethnicities and ages.

To play this video you need to enable JavaScript in your browser. Patients in England with a specific type of incurable breast cancer can now access a life-extending drug on the NHS, two years after it was deemed too expensive by a health body. Enhertu can give patients almost seven extra months to live on average - with some living up to three years longer. Women in Scotland have had access to the drug on the NHS since 2023, and it is available in 26 other European countries. Charities and patients have campaigned for it to be more widely available since 2024, when the National Institute for Health and Care Excellence (NICE) said Enhertu was not good value for money.

Follow this section to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens. Follow this tag to personalize your feed and get instant alerts. Follow Go to your personalized feed WHY FOLLOW? Smart Alerts: Get notified about major news as it happens.

Radiation therapy, treating over half of all cancer patients, involves using specialized machines to direct high-energy beams at tumors, aiming to damage cancer cells while minimizing harm to nearby healthy tissues. Customizing the shape and intensity of radiation beams for each patient leads to solving large-scale constrained optimization problems that need to be solved within tight clinical time-frame. At the core of these challenges is a large matrix that is commonly sparsified for computational efficiency by neglecting small elements. Such a crude approximation can degrade the quality of treatment, potentially causing unnecessary radiation exposure to healthy tissues--this may lead to significant radiation-induced side effects--or delivering inadequate radiation to the tumor, which is crucial for effective tumor treatment. In this work, we demonstrate, for the first time, that randomized sketch tools can effectively sparsify this matrix without sacrificing treatment quality. We also develop a novel randomized sketch method with desirable theoretical guarantees that outperforms existing techniques in practical application. Beyond developing a novel randomized sketch method, this work emphasizes the potential of harnessing scientific computing tools, crucial in today's big data analysis, to tackle computationally intensive challenges in healthcare. The application of these tools could have a profound impact on the lives of numerous cancer patients.

This study presents a comparative methodological analysis of six machine learning models for survival analysis (MLSA). Using data from nearly 45,000 colorectal cancer patients in the Hospital-Based Cancer Registries of São Paulo, we evaluated Random Survival Forest (RSF), Gradient Boosting for Survival Analysis (GBSA), Survival SVM (SSVM), XGBoost-Cox (XGB-Cox), XGBoost-AFT (XGB-AFT), and LightGBM (LGBM), capable of predicting survival considering censored data. Hyperparameter optimization was performed with different samplers, and model performance was assessed using the Concordance Index (C-Index), C-Index IPCW, time-dependent AUC, and Integrated Brier Score (IBS). Survival curves produced by the models were compared with predictions from classification algorithms, and predictor interpretation was conducted using SHAP and permutation importance. XGB-AFT achieved the best performance (C-Index = 0.7618; IPCW = 0.7532), followed by GBSA and RSF. The results highlight the potential and applicability of MLSA to improve survival prediction and support decision making.

Metaphors and metaphorical language (MLs) play an important role in healthcare communication between clinicians, patients, and patients' family members. In this work, we focus on Dutch language data from cancer patients. We extract metaphors used by patients using two data sources: (1) cancer patient storytelling interview data and (2) online forum data, including patients' posts, comments, and questions to professionals. We investigate how current state-of-the-art large language models (LLMs) perform on this task by exploring different prompting strategies such as chain of thought reasoning, few-shot learning, and self-prompting. With a human-in-the-loop setup, we verify the extracted metaphors and compile the outputs into a corpus named HealthQuote.NL. We believe the extracted metaphors can support better patient care, for example shared decision making, improved communication between patients and clinicians, and enhanced patient health literacy. They can also inform the design of personalized care pathways. We share prompts and related resources at https://github.com/aaronlifenghan/HealthQuote.NL

Purpose: Intensity-modulated proton therapy (IMPT) offers precise tumor coverage while sparing organs at risk (OARs) in head and neck (H&N) cancer. However, its sensitivity to anatomical changes requires frequent adaptation through online adaptive radiation therapy (oART), which depends on fast, accurate dose calculation via Monte Carlo (MC) simulations. Reducing particle count accelerates MC but degrades accuracy. To address this, denoising low-statistics MC dose maps is proposed to enable fast, high-quality dose generation. Methods: We developed a diffusion transformer-based denoising framework. IMPT plans and 3D CT images from 80 H&N patients were used to generate noisy and high-statistics dose maps using MCsquare (1 min and 10 min per plan, respectively). Data were standardized into uniform chunks with zero-padding, normalized, and transformed into quasi-Gaussian distributions. Testing was done on 10 H&N, 10 lung, 10 breast, and 10 prostate cancer cases, preprocessed identically. The model was trained with noisy dose maps and CT images as input and high-statistics dose maps as ground truth, using a combined loss of mean square error (MSE), residual loss, and regional MAE (focusing on top/bottom 10% dose voxels). Performance was assessed via MAE, 3D Gamma passing rate, and DVH indices. Results: The model achieved MAEs of 0.195 (H&N), 0.120 (lung), 0.172 (breast), and 0.376 Gy[RBE] (prostate). 3D Gamma passing rates exceeded 92% (3%/2mm) across all sites. DVH indices for clinical target volumes (CTVs) and OARs closely matched the ground truth. Conclusion: A diffusion transformer-based denoising framework was developed and, though trained only on H&N data, generalizes well across multiple disease sites.

Radiation therapy, treating over half of all cancer patients, involves using specialized machines to direct high-energy beams at tumors, aiming to damage cancer cells while minimizing harm to nearby healthy tissues. Customizing the shape and intensity of radiation beams for each patient leads to solving large-scale constrained optimization problems that need to be solved within tight clinical time-frame. At the core of these challenges is a large matrix that is commonly sparsified for computational efficiency by neglecting small elements. Such a crude approximation can degrade the quality of treatment, potentially causing unnecessary radiation exposure to healthy tissues--this may lead to significant radiation-induced side effects--or delivering inadequate radiation to the tumor, which is crucial for effective tumor treatment. In this work, we demonstrate, for the first time, that randomized sketch tools can effectively sparsify this matrix without sacrificing treatment quality.

Fox News anchor Bret Baier has the latest on the Murdoch Children's Research Institute's partnership with the Gladstone Institutes for the'Decoding Broken Hearts' initiative on'Special Report.' A simple selfie could hold hidden clues to one's biological age -- and even how long they'll live. That's according to researchers from Mass General Brigham, who developed a deep-learning algorithm called FaceAge. Using a photo of someone's face, the artificial intelligence tool generates predictions of the subject's biological age, which is the rate at which they are aging as opposed to their chronological age. FaceAge also predicts survival outcomes for people with cancer, according to a press release from MGB.

Cancer remains a leading global health challenge and a major cause of mortality. This study leverages machine learning (ML) to predict the survivability of cancer patients with metastatic patterns using the comprehensive MSK-MET dataset, which includes genomic and clinical data from 25,775 patients across 27 cancer types. We evaluated five ML models-XGBoost, Naïve Bayes, Decision Tree, Logistic Regression, and Random Fores using hyperparameter tuning and grid search. XGBoost emerged as the best performer with an area under the curve (AUC) of 0.82. To enhance model interpretability, SHapley Additive exPlanations (SHAP) were applied, revealing key predictors such as metastatic site count, tumor mutation burden, fraction of genome altered, and organ-specific metastases. Further survival analysis using Kaplan-Meier curves, Cox Proportional Hazards models, and XGBoost Survival Analysis identified significant predictors of patient outcomes, offering actionable insights for clinicians. These findings could aid in personalized prognosis and treatment planning, ultimately improving patient care.